Henry Ford Health System discussed its role in the Moderna vaccine trial after the drugmaker announced today that early data from its mRNA trial showed its vaccine is 94.5% effective. Henry Ford was the only hospital in Michigan and one of about 90 nationally chosen to participate in the trial. Henry Ford was a key site for enrolling minority volunteers who were hardest hit by COVID-19.
Leading the media briefing are Paul Kilgore, M.D., MPH, a Henry Ford co-principal investigator in the vaccine trial, and Kellie McFarlin, M.D., a Henry Ford general surgeon and a volunteer vaccine participant. They were joined by Melanie Ivarsson, Ph.D., chief development officer for Moderna.